Heron Therapeutics, Inc. lost $0.12 per diluted share in fiscal year 2025. This represents a decrease of 33.3% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $0.18 per diluted share. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Heron Therapeutics, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$0.12
YoY-33.3%
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
HRTX EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Heron Therapeutics, Inc.'s diluted earnings per share in fiscal year 2025?
Heron Therapeutics, Inc. lost $0.12 per diluted share in fiscal year 2025.
How fast is Heron Therapeutics, Inc.'s diluted earnings per share growing?
Heron Therapeutics, Inc. (HRTX) diluted earnings per share fell by 33.3% year over year, from -$0.09 to -$0.12 in fiscal year 2025.
What is Heron Therapeutics, Inc.'s diluted earnings per share over the last twelve months?
Heron Therapeutics, Inc. (HRTX) reported a loss of $0.18 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
What was Heron Therapeutics, Inc.'s diluted earnings per share in the most recent quarter?
Heron Therapeutics, Inc. (HRTX) reported -$0.03 in diluted earnings per share in Q2 2026.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Heron Therapeutics, Inc. (HRTX) reported on that line in every period on record.
